Ȳ¿ì¿¬ ¸íÀÇ

Ȳ¿ì¿¬ ¸íÀÇ

  • ¼Ò ¼Ó
    °æÈñ´ëÇб³º´¿ø
  • Áø·á°ú
    »êºÎÀΰú
  • Àü¹®ºÐ¾ß
    ´ÜÀϰø ·Îº¿¼ö¼ú, º¹°­°æ¼ö¼ú, ¾Ç¼ºÁ¾¾ç, ¾ç¼ºÁ¾¾ç, ºñÁ¤»óÃâÇ÷, ÀÚ±ÃÅ»ÃâÁõ

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • °æÈñ´ë ÀÇ´ë ¼®»ç
  • ¼­¿ï´ë ÀÇ´ë ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) °æÈñ´ëÇб³º´¿ø Á¶±³¼ö
  • úÞ) »êºÎÀΰúÀü¹®ÀÇ

¼ö»ó³»¿ª

Awards List
  • ´ëÇѺÎÀξÏÁß°³¿¬±¸È¸ ¿ì¼ö Æ÷½ºÅÍ»ó (2023)
  • ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ ¿ì¼ö ±¸¿¬»ó (2022)
  • ´ëÇѺñ´¢ºÎÀΰúÇÐȸ ÃÖ¿ì¼ö ±¸¿¬»ó (2021)

ÇÐȸȰµ¿

Academic activities
  • 2024 ~ ÇöÀç´ëÇÑ»êºÎÀΰúÇÐȸ º¸ÇèÀ§¿øÈ¸ À§¿ø
  • 2024 ~ ÇöÀç´ëÇѺÎÀξÏÁß°³¿¬±¸È¸ ¿¬±¸ºÐ°úÀ§¿øÈ¸ À§¿ø
  • 2023 ~ ÇöÀç´ëÇѺÎÀÎÁ¾¾çÇÐȸ À¯°üÇÐȸ±³·ù¼ÒÀ§¿øÈ¸ °£»ç
  • 2023 ~ ÇöÀç´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¤º¸Åë½ÅÀ§¿øÈ¸ À§¿ø
  • 2023 ~ 2023 ´ëÇѾϿ¹¹æÇÐȸ ±¹Á¦À§¿ø
  • 2023 ~ ÇöÀç´ëÇÑÀÇÇÐÇмúÁöÆíÁýÀÎÇùÀÇȸ ±âȹ¿î¿µÀ§¿øÈ¸ À§¿ø
  • 2022 ~ ÇöÀç´ëÇѺÎÀÎÁ¾¾çÇÐȸ üºÎ¾Ï ¼¼¼¼ºÎ¿î¿µÀ§¿ø
  • 2022 ~ ÇöÀç´ëÇÑ»êºÎÀΰú·Îº¿¼ö¼úÇÐȸ ÆíÁýÀ§¿øÈ¸ À§¿ø
  • 2022 ~ ÇöÀç´ëÇѺÎÀξÏÁß°³¿¬±¸È¸ À±¸®À§¿ø
  • 2021 ~ ÇöÀç´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ DDT À§¿ø
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 0°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ https://health.chosun.com/site/data/html_dir/2026/03/27/2026032703053.html
¹ßÇ¥³âµµ 2025 ¹ßÇ¥Áö
Á¦ ¸ñ Clinical application of cold atmospheric-pressure plasma: mechanisms and irradiation conditions
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö
Á¦ ¸ñ Determination of ovarian transposition through prediction of postoperative adjuvant therapy in young patients with early stage cervical cancer undergoing surgery: a Korean multicenter retrospective study (KGOG 1042)
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö
Á¦ ¸ñ Lymphadenectomy in clinically early epithelial ovarian cancer and survival analysis (LILAC): a Gynecologic Oncology Research Investigators Collaboration (GORILLA-3002) retrospective study
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö
Á¦ ¸ñ Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology consensus statement
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö
Á¦ ¸ñ Minimally Invasive Sacrohysteropexy Versus Vaginal Hysterectomy with Uterosacral Ligament Suspension for Pelvic Organ Prolapse: a Prospective Randomized Non-Inferiority Trial
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö
Á¦ ¸ñ Endometrioid carcinoma associated with ovarian endometriosis: need for cautions during treatment
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°æÈñ´ëÇб³º´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
02-958-8114
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°æÈñ´ëÇб³º´¿øÀº ȯÀÚ Áß½ÉÀÇ ÀÇ·á ¼­ºñ½º¸¦ Á¦°øÇϸç, ±¹³» ÀÇ·á°è¸¦ ¼±µµÇÏ´Â »ó±ÞÁ¾ÇÕº´¿øÀÔ´Ï´Ù. ÃֽŠÀÇ·á ±â¼ú°ú Àåºñ¸¦ Ȱ¿ëÇÏ¿© ȯÀڵ鿡°Ô ÃÖ»óÀÇ Ä¡·á¸¦ Á¦°øÇÕ´Ï´Ù. ƯÈ÷ ÁßÁõÁúȯ Ä¡·á ¹× ¿¬±¸¿¡ °­Á¡À» º¸À̸ç, ´ÙÇÐÁ¦ ÇùÁø ½Ã½ºÅÛÀ» ÅëÇØ ȯÀÚÀÇ °Ç°­À» ÃÖ¿ì¼±À¸·Î »ý°¢ÇÕ´Ï´Ù. °æÈñ´ëÇб³º´¿øÀº ȯÀÚµéÀÇ ½Å·Ú¿Í ¸¸Á·µµ¸¦ ³ôÀÌ´Â µ¥ ÁÖ·ÂÇϸç, Áö¼ÓÀûÀ¸·Î ÀÇ·á ǰÁú Çâ»ó°ú ¿¬±¸ °³¹ß¿¡ Èû¾²°í ÀÖ½À´Ï´Ù.

°æÈñ´ëÇб³º´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã µ¿´ë¹®±¸ °æÈñ´ë·Î 23 °æÈñ´ëÇб³º´¿ø

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä